Pharmacological Chaperones for Enzyme Enhancement Therapy in Genetic Diseases
- 20 December 2012
- journal article
- review article
- Published by Taylor & Francis in Pharmaceutical Patent Analyst
- Vol. 2 (1) , 109-124
Abstract
Pharmacological chaperone therapy (PCT) is a rather new approach consisting in targeting incorrectly folded proteins by small molecules, thus, facilitating the correct folding of the protein and inducing a recovery of its functionality. Many diseases result from mutations on specific genes; this patent review focuses on those pathologies where PCT has a potential application for enzymatic enhancement. Rare diseases are the main area where PCT has been applied and the most advanced compounds are aiming to cure lysosomal storage disorders such as Fabry, Pompe or Gaucher. Until now, most compounds used as pharmacological chaperones were based on substrate-like chemical structures but recently new nonsubstrate-like and non-inhibitory compounds have been disclosed for Gaucher and Pompe diseases. This initiates a new era for pharmacological chaperones with more diverse chemical structures and binding modes. This review covers the patents relating to enzyme enhancement on pharmacological chaperone therapy. Only an update is presented for Gaucher disease, where PCT is highly applied and recently reviewed.Keywords
This publication has 70 references indexed in Scilit:
- An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay–Sachs or Sandhoff variants)Molecular Genetics and Metabolism, 2011
- Pharmacological Chaperones for Misfolded Gonadotropin-Releasing Hormone Receptors2011
- Fluorous Iminoalditols: A New Family of Glycosidase Inhibitors and Pharmacological ChaperonesChemBioChem, 2010
- Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten diseaseBiochemical and Biophysical Research Communications, 2010
- Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activatorsEuropean Journal of Medicinal Chemistry, 2010
- Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinicsEMBO Molecular Medicine, 2009
- Isofagomine Induced Stabilization of GlucocerebrosidaseChemBioChem, 2008
- Isofagomine increases lysosomal delivery of exogenous glucocerebrosidaseBiochemical and Biophysical Research Communications, 2008
- Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-β-glucosidaseBiochemical Pharmacology, 2007
- High-Throughput Screening for Human Lysosomal β-N-Acetyl Hexosaminidase Inhibitors Acting as Pharmacological ChaperonesChemistry & Biology, 2007